SCHEMBL5207246

SCHEMBL5207246

NC(=O)C1CCC(c2nc(-c3cccc(Cl)c3)c[nH]2)CC1

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
RAB9A P51151 1/20 0.53
SMN1; SMN2 Q16637 1/20 0.53
VCP P55072 4/20 0.44
MEN1 O00255 1/20 0.44
KMT2A Q03164 1/20 0.44
PDE4D Q08499 1/20 0.43
GRM5 P41594 1/20 0.41
CNR2 P34972 3/20 0.41
KDM1A O60341 1/20 0.40
MAOB P27338 1/20 0.40
KMO O15229 1/20 0.39
JAK2 O60674 1/20 0.39
JAK1 P23458 1/20 0.39
IKBKB O14920 1/20 0.39
CHUK O15111 1/20 0.39
GSK3B P49841 1/20 0.39
KDM5B Q9UGL1 1/20 0.38
PARP1 P09874 1/20 0.38
PDGFRB P09619 1/20 0.38
KIT P10721 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5207210 0.83 KDM1A (0.55) VCPMEN1KMT2AKDM1AMAOB
SCHEMBL5207254 0.81 STK4 (0.42) VCPCNR2KDM1AMAOBKDM5B
SCHEMBL27776222 0.80 GABRA1 (0.46) RAB9AKDM1AMAOBPDGFRBKIT
Hydrochloric Acid SCHEMBL311446 0.79 GABRA1 (0.45) RAB9AKDM1AMAOB
SCHEMBL442390 0.76 NPC1 (0.55) RAB9AVCP
SCHEMBL408754 0.76 NPC1 (0.55) RAB9AVCP
SCHEMBL5203627 0.75 NPC1 (0.45) RAB9AVCPMEN1KMT2APDE4D
SCHEMBL5203636 0.75 NPC1 (0.45) RAB9AVCPMEN1KMT2APDE4D
SCHEMBL310851 0.74 SMN1; SMN2 (0.49) SMN1; SMN2
SCHEMBL5204673 0.74 VCP (0.46) VCPJAK2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1306085-B1 2-Cyclohexyl-4-phenyl-1H-imidazole derivatives as ligands for the neuropeptide Y5 receptor NEUROGEN CORP (US) 2007-02-14 EP claimed
US-7034034-B2 Substituted 2-cyclohexyl-4-phenyl-1H-imidazole derivatives NEUROGEN CORPORATION (US) 2006-04-25 US claimed
WO-2003104255-A2 SUBSTITUTED 2-CYCLOHEXYL-4-PHENYL-1H-IMIDAZOLE DERIVATIVES NEUROGEN CORPORATION (US) 2003-12-18 WO claimed
US-20030144290-A1 Substituted 2-cyclohexyl-4-phenyl-1H-imidazole derivatives NEUROGEN CORPORATION 2003-07-31 US claimed
EP-1306085-B1 2-Cyclohexyl-4-phenyl-1H-imidazole derivatives as ligands for the neuropeptide Y5 receptor NEUROGEN CORP (US) 2007-02-14 EP disclosed
US-7034034-B2 Substituted 2-cyclohexyl-4-phenyl-1H-imidazole derivatives NEUROGEN CORPORATION (US) 2006-04-25 US disclosed
WO-2003104255-A2 SUBSTITUTED 2-CYCLOHEXYL-4-PHENYL-1H-IMIDAZOLE DERIVATIVES NEUROGEN CORPORATION (US) 2003-12-18 WO disclosed
US-20030144290-A1 Substituted 2-cyclohexyl-4-phenyl-1H-imidazole derivatives NEUROGEN CORPORATION 2003-07-31 US disclosed
EP-1306085-A1 2-Cyclohexyl-4-phenyl-1H-imidazole derivatives as ligands for the neuropeptide Y5 receptor Neurogen Corporation (US) 2003-05-02 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030144290-A1 Substituted 2-cyclohexyl-4-phenyl-1H-imidazole derivatives NPY5R, NPY4R, NPY1R RAB9A 3491/4885SMN1; SMN2 3438/4885VCP 3862/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.